klacid iv 500mg powder for concentrate for solution for infusion
mylan ire healthcare limited - clarithromycin - powder for concentrate for solution for infusion - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms in the following conditions: lower respiratory tract infections for example, acute and chronic bronchitis, and pneumonia. upper respiratory tract infections for example, sinusitis and pharyngitis. skin and soft tissue infections.
clarithromycin 250mg film-coated tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 250 mg - antibacterials for systemic use
clarithromycin 500mg film-coated tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clarithromycin - film-coated tablet - clarithromycin 500 mg - antibacterials for systemic use
klacid 250 mg film-coated tablets
mylan ire healthcare limited - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections due to susceptible organisms. such infections include: 1. lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas). 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 5. clarithromycin is indicated for the prevention of disseminated mycobacterium avium complex infection in hivinfected patients with cd4 lymphocyte counts less than or equal to 100/mm3. 6. clarithromycin in the presence of acid suppression is indicated for the eradication of h. pylori, resulting in decreased recurrence of duodenal ulcer. (see further information).
klacid la 500mg modified release tablets
mylan ire healthcare limited - clarithromycin - modified-release tablet - 500 milligram(s) - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections for example bronchitis and pneumonia. upper respiratory tract infections for example sinusitis and pharyngitis. skin and soft tissue infections for example folliculitis, cellulitis and erysipelas.
klacid paediatric suspension 125mg/5ml, granules for oral suspension
mylan ire healthcare limited - clarithromycin - granules for oral suspension - 125 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include o lower respiratory tract infections o upper respiratory tract infections o skin and skin structure infections o acute otitis media
klacid 250mg/5ml granules for oral suspension
mylan ire healthcare limited - clarithromycin - granules for oral suspension - 250 mg/5ml - macrolides; clarithromycin - antibacterial for systemic use, macrolide - it is indicated for the treatment of infections caused by susceptible organisms. indications include: lower respiratory tract infections. upper respiratory tract infections. skin and skin structure infections. acute otitis media.
clarithromycin krka 250 mg film-coated tablets
krka, d.d., novo mesto - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin
clarithromycin krka 500 mg film-coated tablets
krka, d.d., novo mesto - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin
erythrocin i.v. powder for solution
amdipharm limited - erythromycin (erythromycin lactobionate) - powder for solution - 500mg - erythromycin (erythromycin lactobionate) 500mg - erythromycins